Biomarker research in occupational health

Journal of Occupational and Environmental Medicine

Volumn 47, Issue 2, 2005, Pages 145-153

  Au, William W ^a,d   Lee, Ernest ^b,c   Christiani, David C ^b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c AIR FORCE INSTITUTE OF TECHNOLOGY   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENE; BIOLOGICAL MARKER; CIGARETTE SMOKE; CYTOCHROME P450 2E1; DRUG METABOLITE; GASOLINE; GLYCOPHORIN A; PLASMA PROTEIN;

APLASTIC ANEMIA; BLOOD TOXICITY; BONE MARROW DEPRESSION; BONE MARROW TOXICITY; CHROMOSOME ABERRATION; DANGEROUS GOODS; DNA STRAND BREAKAGE; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; GENOTOXICITY; HEALTH HAZARD; MACROMOLECULE; MICRONUCLEUS; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH; POPULATION; PROTEOMICS; REVIEW; RISK ASSESSMENT; WORKER; WORKPLACE;

BENZENE; BIOLOGICAL MARKERS; GENETIC MARKERS; HUMANS; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH; RESEARCH;

EID: 13644263993     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jom.0000152922.03953.9a     Document Type: Review

References (92)

1. Christiani DC. Utilization of biomarker data for clinical and environmental intervention. Environ Health Perspect. 1996;104:921-925.
2. Hulka BS, Wilcosky TC, Griffith JD. Biological Markers in Epidemiology. New York: Oxford University Press; 1990.
3. Bonassi S, Au WW. Biomarkers in molecular epidemiology studies for health risk prediction. Mutat Res. 2002;511:73-86.
4. Albertini RJ, Sram RJ, Vacek PM, et al. Biomarkers in Czech workers exposed to 1,3-butadiene: a transitional epidemiologic study. Res Rep Health Eff Inst. 2003;116:1-141.
5. Au WW. Life style factors and acquired susceptibility to environmental disease. Int J Hygiene Environ Health. 2001;204:17-22.
6. Au WW. Susceptibility of children to environmental toxic substances. Int J Hyg Environ Health. 2002;205:1-3.
7. Norppa H. Genetic susceptibility, biomarker response, and cancer. Mutat Res. 2003;544:39-348.
8. Au WW, Sierra-Torres CH, Tyring SK. Acquired and genetic susceptibility to cervical cancer. Mutat Res. 2003;544:361-364.
9. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk Cancer Epidemiol Biomarkers Prev. 2002;11:1513-1530.
10. Mohrenweiser HW, Wilson DM, Jones IM. Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes. Mutat Res. 2003;526:93-125.
11. Shen H, Spitz MR, Qiao Y, et al. Smoking, DNA repair capacity and risk of nonsmall cell lung cancer. Int J Cancer. 2003;107:84-88.
12. Abdel-Rahman SZ, Ammenheuser MM, Ward JB Jr. Human sensitivity to 1,3-butadiene: role of microsomal epoxide hydrolase polymorphisms. Carcinogenesis. 2001;22:415-423.
13. Abdel-Rahman S, El-Zein, R, Ammenheuser M, et al. Variability in human sensitivity to 1,3-butadiene: influence of the allelic variants of the microsomal epoxide hydrolase gene. Environ Mol Mutag. 2003;41:140-146.
14. Zhang L, Hayes RB, Guo W et al. Lack of increased genetic damage in 1,3-butadiene-exposed Chinese workers studied in relation to EPHX1 and GST genotypes. Mutat Res. 2004;558:63-74.
15. Torasson M, Albertini R, Bayard S, et. Al. Applying new technologies to the study of occupational cancer- a workshop summary. Environ Health Perspectives 2004;112:413-416.
16. Goodsaid FM. Genomic biomarkers of toxicity. Opinion Drug Dic Dev. 2003;6:41-49.
17. Waters MD, Olden K, Tennant RW. Toxicogenomic approach for assessing toxicant-related disease. Mutat Res. 2003;544:415-424a.
18. Waters MD, Selkirk JK, Olden K. The impact of new technologies on human population studies. Mutat Res. 2003;544:349-360b.
19. Hagmar L, Bonassi S, Strömberg U, et al. Chromosomal aberrations in lymphocytes predict human cancer - A report from the European Study Group on Cytogenetic Biomarkers and Health (ESCH). Cancer Res. 1998;58:4117-4121.
20. Liou SH, Lung JC, Chen YH, et al. Increased chromosome-type chromosome aberration frequencies as biomarkers of cancer risk in a blackfoot endemic area. Cancer Res. 1999;59:1481-1484.
21. Bonassi S, Hagmar L, Strömberg U, et al, and the European Study Group on Cytogenetic Biomarkers and Health (ESCH). Chromosomal aberrations in lymphocytes predict human cancer independently from exposure to carcinogens. Cancer Res. 2000;60:1619-1625.
22. Smerhovsky Z, Landa K, Rossner P, et al. Risk of cancer in an occupationally exposed cohort with increased level of chromosomal aberrations. Environ Health Perspect. 2001;109:41-5.
23. Hussain SP, Harris CC. p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat Res. 1999;428:23-32.
24. Vahakangas KH, Bennett WP, Castren K, et al. p53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res. 2001;61:4350-4356.
25. Mau L, Hruban R, Boyle JO, et al., Detection of onocogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res. 1994;54:1634-1637.
26. Scott FM, Modali R, Lehman TA, et al. High frequency of K-ras codon 12 mutations in bronchoalveolar lavage fluid of patients at high risk for second primary lung cancer. Clin Cancer Res. 1997;3:479-482.
27. Sammett DL, Lee EW, Kocsis JJ, Snyder R. Partial hepatectomy reduces both metabolism and toxicity of benzene. J Toxicol Environ Health. 1979;5:785-792.
28. Bolcsak LE, Nerland DE. Inhibition of erythropoiesis by benzene and benzene metabolites. Toxicol Appl Pharmacol. 1983;69:363-368.
29. Goldstein BD. Introduction: Occam's razor is dull. Environ Health Perspect. 1989;82:3-6.
30. Snyder R, Kocsis JJ. Current concepts of chronic benzenetoxicity. CRC Crit Rev Toxicol. 1975;3:265-288.
31. Forni A, Pacificao E Limonta A. Chromosome studies in workers exposed to benzene or toluene or both. Arch Environ Health. 1971;22:373-378a.
32. Forni A, Cappellini A, Pacifico E, Vigliani E. Chromosome changes and their evolution with past exposure to benzene. Arch Environ Health. 1971;23:385-391b.
33. Hite T, Pecharo M, Smith I, Thornton S. The effect of benzene in micronuclei test. Mutat Res. 1980;77:149-155.
34. Tice RR, Vogt TF, Costa DL. Cytogenetic effects of inhaled benzene in murine bone marrow in genotoxic effect of airborne agents. Environ Sci Res. 1982;25:257-275.
35. Sanz GF, Sanz MA, Vallespi T. Etiopathogency, prognosis and therapy of myelodysplastic syndromes. Hematol Cell Ther. 1997;39:277-294.
36. Hayes RB, Yin SN, Dosemeci M, Linet M. Benzene and lymphohematopoietic malignancies in humans. Am J Ind Med. 2001;40:117-126.
37. Cronkite EP, Drew RT, Inoue T, et al. Hematotoxicity and carcinogenicity of inhaled benzene. Environ Health Perspect. 1989;82:97-108.
38. Maltoni C, Ciliberti A, Cotti G, et al. Benzene, an experimental multipotential carcinogen: results of the long-term bioassays performed at the Bologna Institute of Oncology. Environ Health Persp. 1989;82:109-124.
39. Hanke J, Dutkiewics T, Piotrowski J. Absorption of benzene through the skin in man. Med Pract. 1961;12:413-426.
40. Snyder R, Witz G, Goldstein BD. The toxicology of benzene. Environ Health Perspect. 1993;100:293-306.
41. Ayres PH, Taylor WD. Solvents. In: AH Hayes, ed. Principles and Methods of Toxicology. 2nd ed. New York: Raven Press Ltd; 1989:111.
42. Fishbein L. Benzene: uses, occurrence, and exposure. In: Fishbein L, O'Neill OK, eds. Environmental Carcinogens: Methods of Analysis and Exposure Measurement. Vol 10. Benzene and Alkylated Benzenes. Lyon, France: IARC Sci Publ No 85:67-108; 1988.
43. Wallace LA Pellizzari ED. Personal air exposures and breath concentrations of benzene and other volatile hydrocarbons for smokers and nonsmokers. Toxicol Lett. 1986;35:113-116.
44. Toxnet Benzene Occupational Exposure Standards. Available at: http://toxnet.nlm.nih.gov/cgi-bin/sis/search/f?./temp/~ig0UhD:1; Internet; accessed December 9, 2004.
45. Nomiyama K, Nomiyama H. Respiratory retention, uptake, and excretion of organic solvents in man. Int Arch Arbeitsmeed. 1974;32:75-83.
46. Porteous JW, Williams RT. Studies in detoxication: the isolation of phenol, catechol, quinol and hydroxyquinol from the ethereal sulfate fraction of the urine of rabbits receiving benzene orally. Biochem J. 1949;44:56-61.
47. 1) benzene. Biochem J. 1953;45:231-238.
48. Williams RT. Detoxication Mechanism. London: Chapman and Hall; 1959:188-194.
49. Jaffe M. Uber die Aufspaltung des Banzolrings im Organismus. I Mitteilung. Das Auftretan von Muconsaure im Harn nach Darreichung von Benzol. Hoppeo-Seyl Z Physiol Chem. 1909;62:58-67.
50. Carmella SG, LaVoie EJ, Hecht SS. Quantitative analysis of catechol and 4-methyl catechol in human urine. Food Chem Toxicol. 1982;20:587-590.
51. Deisinger PJ, Hill TS, English C. Human exposure to natural occurring hydroquinone. J Toxicol Environ Health. 1996;47:31-46.
52. Ducos P, Gaudin R, Robert A, et al. Improvement in HPLC analysis of urinary trans, trans Muconic acid, a promising substitute for phenol in the assessment of benzene exposure. Int Arch Occup Environ Health. 1990;62d:529-534.
53. Hotz P, Carbonnelle P, Haufroid V, et al. Biological monitoring of vehicle mechanics and other workers exposed to low concentrations of benzene. Int Arch Occup Environ Health. 1997;70:29-40.
54. Westoo G. On the metabolism of sorbic acid in the mouse. Acta Chem Scan. 1964;18:1373-1378.
55. Van Sitter NJ, Boogaard PJ, Beulink GDJ. Application of the urinary S-phenylmercapturic acid test as a biomarker for low levels of exposure to benzene in industry. Br J Ind Med. 1993;50:460-469.
56. Ghittori S, Maestri L, Fiorentino ML, Imbriani M. Evaluation of occupational exposure to benzene by urinalysis. Int Arch Occup Environ Health. 1995;67:195-200.
57. Ong CN, Kok PW, Shi CY, et al. Biomarkers of exposure to low concentrations of benzene: a field assessment. Occup Environ Med. 1996;53:328-333.
58. Ghittori S, Fiorentino ML, Maestri L, et al. Urinary excretion of unmetabolized benzene as an indicator of benzene exposure. J Toxicol Environ Health. 1993;38:233-243.
59. Perbellini L, Faccini GB, Pasini F, et al. Environmental and occupational exposure to benzene by analysis of breath and blood. Br J Ind Med. 1988;45:345-352.
60. Pekari K, Vainiotalo S, Heikkila P, et al. Biological monitoring of occupational exposure to low levels of benzene. Scand J Work Environ Health. 1992;18:317-322.
61. Verdina A, Galati R, Falasca G, et al. Metabolic polymorphisms and urinary biomarkers in subjects with low benzene exposure. J Toxicol Environ Health. 2001;64:607-618.
62. Kenyon EM, Kraichely RE, Hudson KT, Medinsky MA. Differences in rates of benzene metabolism correlate with observed genotoxicity. Toxicol Appl Pharmacol. 1996;136:49-56.
63. Valentine JL, Lee SS, Seaton MUJ, et al. Reduction of benzene metabolism and toxicity in mice that lack CYP2E1 expression. Toxicol Appl Pharmacol. 1996;141:205-213.
64. Kalf GF. Recent advances in the metabolism and toxicity of benzene. Criti Rev Toxicol. 1987;18:141-159.
65. Tice RR, Vogt TF, Costa DL. Effect of sex, strain, age, and route of exposure in benzene-induced sister chromatid exchange (SCE) in murine bone marrow. Environ Mutagen. 1981;3:338-339.
66. Gad-El Karim MM, Ramanujam, VMA, Legator MS. Correlation between the induction of micronuclei in bone marrow by benzene exposure and the excretion of metabolites in urine of CD-1 mice. Toxicol Appl Pharmcol. 1986;85:464-477.
67. 1 mice: retrospective analysis of peripheral blood smears from the NTP carcinogenesis bioassay. Mutat Res. 1985;143:55-59.
68. Luke CA, Tice RR, Drew RT. The effect of exposure regiment and duration on benzene-induced bone-marrow damage in mice. I. sex comparison in DBA/2 mice. Mutat Res. 1988;186:252-271.
69. Seaton MJ, Schlosser PM, Bon JA, Medinsky MA. Benzene metabolism by human liver microsomes in relation to cytochrome P450 2E1 activity. Carcinogenesis. 1994;15:1799-1806.
70. Seaton MJ, Schlosser PM, Bond JA, MEdinsky MA. The potential influence of interindividual variation in phase I and II metabolism of benzene on benzene toxicity. Toxicologist. 1995;15:58-63.
71. Ross D. Metabolic basis of benzene toxicity. Eur J Hematol. 1996;60(suppl):111-118.
72. Cadenas E, Hochstein P, Ernster L. Proand antioxidant functions of quinones and quinone reductases in mammalian cells. Adv Enzymol Relat Areas Mol Biol. 1992;65:97-146.
73. Ross D, Kepa JK, Winski SL, et al. NAD (P) H: quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact. 2000;129:77-97.
74. 1. Cancer Res. 2003;63:929-935.
75. 609C→T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res. 1997;57:2839-2842.
76. Wiesel C, Yu R, Roy A, Georgopoulos P. Biomarkers of environmental benzene exposure. Environ Health Perspect. 1996;104(suppl 6):1141-1149.
77. Latriano L, Goldstein BD, Witz G. Formation of muconaldehyde, an open-ring metabolite of benzene, in mouse liver microsomes: an additional pathway for toxic metabolites. Proc Natl Acad Sci USA. 1986;83:8356-8360.
78. Witz G, Zhang Z, Goldstein BD. Reactive ring-opened aldehyde metabolites in benzene hematotoxicity. Environ Health Perspect. 1996;104:1195-1199.
79. Zhang L, Eastmond DA, Smith MT. The nature of chromosomal aberrations detected in humans exposed to benzene. Critical Rev Toxicol. 2002;32:1-42.
80. Rossi A, Guarnieri C, Rovesti S, et al. Genetic polymorphisms influence variability in benzene metabolism in humans. Pharmacogenetics. 1999;9:445-451.
81. Brown EA, Shelly ML, Fisher JW. A pharmacokinetic study of occupational and environmental benzene exposure with regard to gender. Risk Anal. 1998;18:205-213.
82. Forni A. Benzene-induced chromosome aberrations: a follow-up study. Environ Health Perspect. 1996;104S:1309-12.
83. Robertson ML, Eastmond DA, Smith MT. Two benzene metabolites, catechol and hydroquinone, produce a synergistic induction of micronuclei and toxicity in cultured human lymphocytes. Mutat Res. 1991;249:201-209.
84. Subrahmanyam VV, Ross D, Eastmond DA, Smith MT. Potential role of free radicals in benzene-induced myelotoxicity and leukemia. Free Rad Biol Med. 1991;11:495-515.
85. Liu L, Zhang Q, Feng J, et al. The study of DNA oxidative damage in benzene-exposed workers. Mutat Res. 1996;370:145-150.
86. Joo WA, Sul D, Lee DY et al. Proteomic analysis of plasma proteins of workers exposed to benzene. Mutat Res. 2004;558:35-44.
87. Golomb HM, Alimena G, Rowley JD, et al. Correlation of occupation and karyotype in adults with acute nonlymphocytic leukemia. Blood. 1982;60:404-411.
88. Groupe Francais de Cytogenetique Hematologique. Chromosome analysis of 63 cases of secondary nonlymphoid blood disorders: a cooperative study. Cancer Genet Cytogenet. 1984;12:95-104.
89. Pople JE, Ball RL, Padgett MJ, Aston JP. Construction of a database of benzene biological monitoring. Toxicol Lett. 2002;134:301-304.
90. Aston JP, Ball RL, Pople JE, et al. Development and validation of a competitive immunoassay for urinary S-phenylmercapturic acid and its application in benzene biological monitoring. Biomarkers. 2002;7:103-112.
91. Sram RJ, Rossner P, Smerhovsky Z. Cytogenetic analysis and occupational health in the Czech Republic. Mutat Res. 2004;566:21-48.
92. Au WW, Sierra-Torres H, Cajas-Salazar N, et al. Cytogenetic effects from exposure to mixed pesticides and the influence from genetic susceptibility. Environ Health Persp. 1999;107:501-505.